Drugs Made In America Acquisition Corp. (DMAAU) Net Cash Flow (2025)

Drugs Made In America Acquisition's (DMAAU) quarterly Net Cash Flow came in at $5420.0 in Q4 2025, up 5261.9% on a QoQ basis from -$105.0 in Q3 2025.

Drugs Made In America Acquisition Corp. (DMAAU) Net Cash Flow (2025) Analysis & Trends

Drugs Made In America Acquisition (DMAAU) has 1 years of Net Cash Flow data on file, last reported at $5420.0 in Q4 2025.

Quarterly Net Cash Flow changed N/A year-over-year to $5420.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4786.0 (changed N/A YoY) and the FY2025 annual result came in at $4786.0, up 254.26% from the prior year.
Net Cash Flow advanced to $5420.0 in Q4 2025, from -$105.0 in the prior quarter.
In the past five years, Net Cash Flow ranged from a high of $5420.0 in Q4 2025 to a low of -$428.0 in Q1 2025.

Download Data